Drug maker Valeant announced it will cut ties with the speciality pharmacy it is accused of using to fake sales.
Advertisement
He added that Valeant had “lost confidence in Philidor’s ability to continue to operate in a manner that is acceptable” to both the company and the patients and doctors it serves. He even invoked Warren Buffett’s purchase of American Express (AXP) stock at a bargain basement price back in 1963 after it tanked in the wake of a loan scandal. Prior to that, shareholders barely had any idea about the existence of Valeant’s network of small pharmacies. Numerous rest employ independent specialty pharmacies that can haggle with insurers and link patients to programs under which drugmakers cover their out-of-pocket costs. Wilshire did not return a call seeking comment. “In the meantime, we expect the business to perform well”.
“Valeant has informed Philidor that to the extent that managed care plans will no longer reimburse prescriptions in process, Valeant will fill them at the company’s expense”, the Laval-based company said.
According to the company’s spokesperson Mike DeAngelis, CVS now maintains a broad national network of 68,000 pharmacies. It also asked them to use the identification number of a different pharmacy if an insurer wouldn’t work with Philidor. CVS is one of the United States’s largest pharmacies. Others, such as Anthem, were said to be preparing similar moves.
Philidor, said industry executives, operated unlike traditional and specialty pharmacies. His lawyer explained that Reitz had to protect himself from “massive potential” liability.
So, what’s the problem with Valeant’s drugs?
Mr. Ackman said Valeant made a “meaningful mistake” for underinvesting in public relations since the company only answered the short seller’s allegation with a blunt denial.
Hedge fund mogul William Ackman told his investors on Friday that he was confident in his bet on Valeant Pharmaceuticals but faulted the company for a weak response to fraud allegations that have sunk its stock.
Standard & Poor’s Ratings Services on Friday lowered Valeant Pharmaceuticals worldwide Inc.’s credit rating by one notch to B+ from BB-, citing the company’s mounting legal and regulatory problems related to its affiliate Philidor RX Services.
Valeant had nurtured Philidor in its infancy when it sold only two Valeant acne drugs by mail order. Philidor was shutting down operations, he said.
“We understand that patients, doctors and business partners have been disturbed by the reports of improper behaviour at Philidor, just as we have been”, Pearson said.
At its peak, Valeant accounted for 6.1% of Canada’s S&P/TSX Composite Index, as battered energy- and mining-sector stocks shrank on the country’s flagship benchmark.
Advertisement
“My expectation today is that the market closes relatively close to where it is now – not much above, not much below”, said Bob Phillips, managing principal of Spectrum Management Group in Indianapolis.
